001). The score at month 6 and 12 in the PCBT group was significantly lower than in the check details pharmacotherapy group (P < 0.05 and P < 0.01), respectively. The response rate in the PCCT group was 100% at months 1, 3, 6, and 12, significantly greater than the pharmacotherapy group or PCBT group (Fisher's exact test, P < 0.001) (Table 2). No significant differences in response rates between the pharmacotherapy group and PCBT group were found at any time-point, although there was a trend difference between the two groups at month 12 (Table

2). Remission rates were higher in the PCCT group (≥63.9%) than in pharmacotherapy Inhibitors,research,lifescience,medical group or PCBT group at month 1, 3, 6, and 12, respectively (P < 0.0001; Table 2). There was no significantly different remission rate between the PCBT group and the

Inhibitors,research,lifescience,medical pharmacotherapy group (Fisher’s exact test, P > 0.05) (Table 2). The social-occupational functioning ANCOVA analysis showed that GAF was significantly different overall (P < 0.001). The GAF score showed a significantly greater increase in the PCCT (P < 0.001) group than in the pharmacotherapy group and PCBT group over the treatment time. The repeated measures analysis of variance showed that the interaction of treatments and time significantly affected the GAF score (P < 0.0001). The ANOVA post hoc tests showed that there was no difference in the GAF scores before Inhibitors,research,lifescience,medical treatment among the three groups (P > 0.05). Compared with the baseline, the average GAF score was significantly Inhibitors,research,lifescience,medical increased at month 1 in the PCCT group (P < 0.001) and remained at a significantly higher level at months 3, 6, and 12. At months 1, 3, 6, and 12, the GAF score was higher in the PCCT group than in the pharmacotherapy group and PCBT group (P < 0.001) (Table 2). At month 3, the GAF score increased in the pharmacotherapy group

and in the PCBT group (P < 0.001) when compared with the baseline. Factors correlated Inhibitors,research,lifescience,medical with the efficacy of PCCT Multiple linear regression analysis was performed using the Y-BOCS-SR score as a dependent variable, and gender, education (year), duration of OCD, severity of symptom, and insight as independent variables to investigate Endocrine Reviews the correlated factors with the efficacy of PCCT. The results show that only insight entered the formula at week 2 (R2 = 0.52, P = 0.025), week 4 (R2 = 0.59, P = 0.025), month 3 (R2 = 0.76, P = 0.001), month 6 (R2 = 0.70, P = 0.003), and month 12 (R2 = 0.64, P = 0.007), respectively. Relapse rates and ITT During follow-up, there were 15 (39.5%) participants in the pharmacotherapy group, 18 (52.9%) in the PCBT, and 36 (100%) in the PCCT that initially responded to the treatments, but 8 (53.3%) in the pharmacotherapy group, 6 (33.3%) in the PCBT, and 2 (5.6%) in the PCCT group relapsed (Fisher exact test, P < 0.001).